Hematoporphyrin derivative rescue from toxicity caused by chemotherapy or radiation in a murine leukemia model (L1210).

Hematoporphyrin [1,3,5,8-tetramethyl-2,4-bis(hydroxyethyl)-porphin-6,7-dipropio nic acid dihydrochloride derivative] (HPD) is a compound that was studied in a number of laboratories because of its cytocidal activity after activation by light. Modification of immune function seen during the photochemotherapeutic studies prompted attempts to determine the effect of HPD on the immune and hemopoietic systems. Splenic hyperplasia as well as marrow hypercellularity were noted in mice treated with HPD. In vitro phytohemagglutinin or lipopolysaccharide stimulation of spleen lymphocytes caused normal or scant increases in blast transformation compared to the stimulation index for lymphocytes from untreated animals. HPD treatment did not significantly alter production of antibody to sheep red blood cells, as evaluated by hemagglutination or hemolytic assay. In contrast, HPD treatment did promote an increased number of spleen colonies in lethally irradiated mice transfused with syngeneic bone marrow. The capacity of HPD to increase the number of bone marrow and spleen cells has been exploited to accelerate the recovery from peripheral leukopenia induced in animals by previous drug or radiation treatment. The time for full return from severe leukopenia induced by an antimetabolite compound (5-fluorouracil) or an alkylating agent (cyclophosphamide or X-rays was significantly shorter in mice treated with HPD than in controls. Furthermore, improved survival was demonstrated in irradiated mice after HPD treatment. Finally, HPD treatment of L1210 leukemic mice did not affect the antitumor activity of cyclophosphamide. If the properties described here be confirmed, HPD might contribute to recovery of leukopenic cancer patients.

[1]  L Ricci,et al.  HAEMATOPORPHYRIN‐TREATED MURINE LYMPHOCYTES: IN VITRO INHIBITION OF DNA SYNTHESIS AND LIGHT‐MEDIATED INACTIVATION OF CELLS RESPONSIBLE FOR GVHR * , 1981, Photochemistry and photobiology.

[2]  M W Berns,et al.  Laser photoradiation therapy of cancer. , 1986, Cancer research.

[3]  D. I. Edwards,et al.  The interaction of reduced metronidazole with DNA. , 1978, Biochemical pharmacology.

[4]  R. E. Thoma,et al.  Interstitial photoradiation therapy for primary solid tumors in pet cats and dogs. , 1981, Cancer research.

[5]  J E Kaufman,et al.  Photoradiation therapy for the treatment of malignant tumors. , 1978, Cancer research.

[6]  A Nicolin,et al.  Immunological and cytogenetic characterization of lymphocitic mouse leukemias after treatment with antineoplastic drugs. , 1978, Pharmacological research communications.

[7]  M. Schreier,et al.  T cell control of the antibody response to the T-independent antigen, DAGG-Ficoll. , 1982, Journal of immunology.

[8]  H. Claman,et al.  Thymus-Marrow Cell Combinations. Synergism in Antibody Production.∗ , 1966, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[9]  V. Oliverio,et al.  Clinical pharmacology of anticancer drugs. , 1977, Seminars in oncology.

[10]  J. Bertino.  "Rescue" techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment. , 1977, Seminars in oncology.

[11]  J. Spivak,et al.  Tumor-promoting phorbol esters stimulate myelopoiesis and suppress erythropoiesis in cultures of mouse bone marrow cells. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Chase,et al.  Preparation of antigens and antibodies , 1967 .

[13]  P. Schein,et al.  Immunosuppressive and cytotoxic chemotherapy: long-term complications. , 1975, Annals of internal medicine.

[14]  S. Spiegelman,et al.  Protection by testosterone from fluorouracil-induced toxicity without loss of anticancer acitvity against autochthonous murine breast tumors. , 1980, Cancer research.

[15]  A. Turner,et al.  Effect of misonidazole therapy on human granulopoietic stem cells. , 1980, Cancer treatment reports.

[16]  G. Lyman,et al.  The use of lithium carbonate to reduce infection and leukopenia during systemic chemotherapy. , 1980, The New England journal of medicine.

[17]  A. Nicolin,et al.  Inhibition of Cellular DNA Synthesis and Lack of Antileukemic Activity by Non-Photoactivated Hematoporphyrin Derivative , 1981, Tumori.

[18]  S. Feig,et al.  Autologous bone marrow transplantation in patients with cancer. , 1980, Experimental hematology.

[19]  J. Marsh,et al.  Allopurinol modification of the toxicity and antitumor activity of 5-fluorouracil. , 1980, Cancer research.

[20]  T. Spector.  Inhibition of urate production by allopurinol. , 1977, Biochemical pharmacology.

[21]  T J Dougherty,et al.  Photoradiation in the treatment of recurrent breast carcinoma. , 1979, Journal of the National Cancer Institute.

[22]  R. Chlebowski,et al.  Clinical and Pharmacokinetic Effects of Combined Warfarin and 5-Fluorouracil in Advanced Colon Cancer , 1982 .

[23]  A. Goldstein,et al.  The Fundamental Concepts of Pharmacology. (Book Reviews: Principles of Drug Action. The Basis of Pharmacology) , 1970 .

[24]  D. Metcalf,et al.  Inhibition by mouse serum of hemopoietic colony formation in vitro. , 1976, Experimental hematology.

[25]  S. Cha,et al.  COFORMYCIN AND DEOXYCOFORMYCIN: TIGHT-BINDING INHIBITORS OF ADENOXINE DEAMINASE , 1978 .

[26]  A. Goldin,et al.  Adoptive immunotherapy in BALB-c times DBA-2 Cr F1 mice bearing an immunogenic subline of L1210 leukemia. , 1974, Cancer research.

[27]  P Franco,et al.  In vitro hematoporphyrin (Hpd) inhibitory effects on some immunological assays. , 1983, International journal of immunopharmacology.

[28]  J. Lokich.  Managing chemotherapy-induced bone marrow suppression in cancer. , 1976, Hospital practice.

[29]  A. Weiss,et al.  Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. , 1976, Cancer treatment reports.

[30]  J. Marsh.  The effects of cancer chemotherapeutic agents on normal hematopoietic precursor cells: a review. , 1976, Cancer research.

[31]  R. Benjamin,et al.  Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high‐dosage schedule , 1974, Cancer.

[32]  A. Bloch,et al.  Prevention by testosterone of the intestinal toxicity caused by the antitumor agent 3-deazauridine. , 1974, Cancer research.

[33]  W. Creasey,et al.  Clinical effects and pharmacokinetics of different dosage schedules of adriamycin. , 1976, Cancer research.

[34]  A. Rubin,et al.  Mitogenic and co-mitogenic properties of hemin. , 1981, Journal of immunology.

[35]  E. Cadman.  Toxicity of Chemotherapeutic Agents , 1977 .

[36]  G. Mathé,et al.  DISCUSSION PAPER: EXPERIMENTAL AND CLINICAL IMMUNOPHARMACOLOGY DATA APPLICABLE TO CANCER IMMUNOTHERAPY , 1976, Annals of the New York Academy of Sciences.